Foster City Newswire
Comprehensive Real-Time News Feed for Foster City, CA.
Results 1 - 4 of 4 for "u:marketwatch.com" in Foster City, CA
Gilead Sciences Inc. received U.S. Food and Drug Administration approval for its Epclusa hepatitis C combination drug and priced the treatment below its older drugs for the disease. Shares of the Foster City, Calif., company, which dominates the market for hepatitis C drugs, rose 3.6% to $81.09 in afternoon trading in New York. Comment?
Gilead Sciences Inc. said revenue from its hepatitis C drugs fell 5.6% in the first quarter as sales of Harvoni and Sovaldi fell short of expectations, suggesting competition is eating into the company's hold on a hot corner of the drug market. The Foster City, Calif., biopharmaceutical company dominates the market for treating hepatitis C, inflammation of the liver that doesn't always show symptoms. Comment?
Gilead Sciences Inc. said the U.S. Food and Drug Administration granted a priority review of its experimental hepatitis C combination drug. The Foster City, Calif., drugmaker filed a new drug application for the treatment--a combination of the biopharmaceutical company's Sovaldi with velpatasvir--in late October. Comment?
The Foster City, Calif.-based payments network is in advanced negotiations to buy its European counterpart--Visa Europe--for about $22 billion in a deal that would unite Visa's global operations under one roof, according to people familiar with the matter. which has held sporadic talks over the years with Visa Europe, confirmed in recent months that it was moving ahead with negotiations and would try to finish the deal by the end of October. Comment?
- « Previous
- Next »
Copyright © 2016 Topix LLC